Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

CDXC Relative to the S&P 500

CDXC Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the ChromaDex Corp. (NASD:CDXC) seasonal charts above shows that a Buy Date of December 8 and a Sell Date of March 16 has resulted in a geometric average return of 21.37% above the benchmark rate of the S&P 500 Total Return Index over the past 16 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 16 years by an average of 31.75% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.? The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services.? The majority of the revenue is earned from the Consumer Products segment.

To download CDXC seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: CDXC